FDMT Insider Nancy Miller-Rich Buys 50,000 Shares

Nancy Miller-Rich recently acquired 50,000 shares of FDMT on June 17, 2026. The transaction was recorded at no cost per share, which is common in certain types of equity awards. This insider activity is often watched by investors for potential signals about the company's future.

Other Institutional Activity in FDMT

Several institutional investors have made notable changes to their FDMT holdings. Janus Henderson Group PLC increased its stake by 611,276 shares, ending with over 5.2 million shares valued at approximately $48.9 million. On the other hand, RA Capital Management, L.P. reduced its holdings by 603,432 shares, now holding just over 5 million shares worth about $47 million. Goldman Sachs Group Inc trimmed its position by 97,467 shares, leaving it with approximately 4.2 million shares valued at $39.2 million. Meanwhile, BlackRock, Inc. added 80,427 shares, bringing its total to about 4.1 million shares worth $38.6 million.

4D Molecular Therapeutics, Inc. Stock Down 38.1%

Shares of FDMT are currently trading around $9.42. The stock has experienced various adjustments by institutional investors, reflecting ongoing interest and activity in the market. While specific valuation metrics like P/E ratios are not provided, the trading price and peer activity offer some insight into the current market sentiment.

Insider Buying and Selling at 4D Molecular Therapeutics, Inc.

In addition to Nancy Miller-Rich, several other insiders have also acquired shares of FDMT. On June 17, 2026, Charles Theuer, Glenn Sblendorio, Susannah Gray, John Milligan, and Jacob Chacko each bought 50,000 shares, with John Milligan purchasing 75,000 shares. These transactions were not part of any pre-planned trading program.

Analysts Set New Price Targets

FDMT has received positive attention from several analysts. On March 30, 2026, Jefferies assumed coverage with a buy rating and a price target of $21. Earlier, on March 20, 2026, HC Wainwright & Co. reiterated its buy rating with a target of $36. RBC Capital maintained its buy rating with a $35 target on March 19, 2026. These ratings suggest a bullish outlook among analysts.

Bottom Line

Insider purchases like those by Nancy Miller-Rich often attract attention as potential indicators of confidence in FDMT's future. The stock, trading at $9.42, has seen varying levels of interest from institutional investors and analysts alike. While 13F filings and insider transactions provide valuable insights, they are backward-looking and should be considered alongside other market factors.